Quantcast
Environmental Health Perspectives Free Trail Issue
Author Keyword Title Full
About EHP Publications Past Issues News By Topic Authors Subscribe Press International Inside EHP Email Alerts spacer
Environmental Health Perspectives (EHP) is a monthly journal of peer-reviewed research and news on the impact of the environment on human health. EHP is published by the National Institute of Environmental Health Sciences and its content is free online. Print issues are available by paid subscription.DISCLAIMER
spacer
NIEHS
NIH
DHHS
spacer
Current Issue

EHP Science Education Website




Comparative Toxicogenomics Database (CTD)

spacer
Environmental Health Perspectives Volume 109, Number 2, February 2001 Open Access
spacer
Associations of Blood Levels of PCB, HCHs, and HCB with Numbers of Lymphocyte Subpopulations, in Vitro Lymphocyte Response, Plasma Cytokine Levels, and Immunoglobulin Autoantibodies

Volker Daniel,1 Wolfgang Huber,2 Klausdieter Bauer,3 Caner Suesal,1 Christian Conradt,4 and Gerhard Opelz1

1Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany; 2Private Practice, Heidelberg-Wieblingen, Germany; 3Labor PD Dr. K. Bauer, Saarbrücken, Germany; 4Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany

Abstract

Pentachlorophenol (PCP) , hexachlorocyclohexane-alpha, -ß, and -gamma (HCH-alpha, -ß, and -gamma) , polychlorinated biphenyls (PCBs) , and hexachlorobenzene (HCB) are widely distributed industrial chemicals. They are suspected to induce immunologic impairments in exposed individuals. We examined dose-response relationships of blood levels of these chemicals with cellular (numbers of lymphocyte subpopulations, in vitro lymphocyte response) or humoral (plasma cytokine levels, immunoglobulin autoantibodies) immunologic dysfunctions. We studied 146 patients who had been occupationally exposed primarily to PCBs for more than 6 months. Lymphocyte subpopulations, in vitro responses to mitogens and allogeneic stimulator cells, plasma neopterin, cytokines, soluble cytokine receptors, soluble adhesion molecules, anti-Ig autoantibodies, and liver transaminases were determined. Blood levels of the different compounds were strongly correlated with one another. There were only weak dose-response relationships between blood levels of PCBs with cellular immune parameters, and of HCHs and HCB with humoral immune parameters. An exception was the statistically significant negative association of HCB with interferon-gamma (IFN-gamma) , indicating that HCB has a significant impact on Th1 lymphocytes. Patients with HCB blood levels above the mean of 1,109 ng/L more often had undetectable IFN-gamma blood levels than patients below the mean. Patients with increased PCB 138 (> 710 ng/L) had more frequently undetectable interleukin-4 blood levels than patients with PCB 138 below the mean, and patients with increased PCB 101 (> 31 ng/L) more often had low DR+ cell counts in the blood (< 190/µL) than patients with PCB 101 below the mean. To assess possible cumulative effects, we compared patients who had blood levels of all compounds below background with patients who had blood levels of all compounds above background. Patients with low or absent blood levels of the compounds studied had higher IFN-gamma plasma levels, providing some evidence for a cumulative effect of several weakly active compounds. In conclusion, exposure to PCBs, HCB, or HCHs is associated with weak immunologic abnormalities. These results contrast with those obtained in earlier studies of blood levels of PCP, which showed a strong dose-dependent relationship with immunologic impairments. Our data suggest that long-term exposure of patients to HCB suppresses IFN-gamma production. Key words: , , , , , . Environ Health Perspect 109:173-178 (2001) . [Online 25 January 2001]

http://ehpnet1.niehs.nih.gov/docs/2001/109p173-178daniel/ abstract.html

Address correspondence to V. Daniel, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-60120 Heidelberg, Germany. Telephone: +49 6221 56 4018. Fax: +49 6221 56 4200. E-mail: Volker_Daniel@med.uni-heidelberg.de

We acknowledge the skillful technical assistance of G. Schmeckenbecher, N. Cetinkaya, M. Kutsche-Bauer, C. Hoffmann, R. Seemuth, and N. Schwind.

Received 31 March 2000 ; accepted 28 September 2000.


The full version of this article is available for free in HTML or PDF formats.
spacer
 
Open Access Resources | Call for Papers | Career Opportunities | Buy EHP Publications | Advertising Information | Subscribe to the EHP News Feeds News Feeds | Inspector General USA.gov